tiprankstipranks
Trending News
More News >
HABA Laboratories, Inc. (JP:4925)
:4925
Japanese Market
Advertisement

HABA Laboratories, Inc. (4925) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4925

HABA Laboratories, Inc.

(4925)

Rating:61Neutral
Price Target:
¥1,815.00
▲(10.00%Upside)
HABA Laboratories' overall stock score reflects a mix of strengths and challenges. The company's solid financial stability, as indicated by its strong balance sheet and improving cash flow, is a significant positive factor. However, the company faces challenges with revenue growth and profitability, impacting its income statement negatively. Technical analysis suggests a neutral market position, while the valuation presents an attractive opportunity due to a low P/E ratio and reasonable dividend yield.

HABA Laboratories, Inc. (4925) vs. iShares MSCI Japan ETF (EWJ)

HABA Laboratories, Inc. Business Overview & Revenue Model

Company DescriptionHABA Laboratories, Inc. (4925) is a Japanese company that specializes in the development, manufacturing, and sale of cosmetics and skincare products. The company is known for its commitment to using additive-free ingredients, catering to customers who prioritize safety and quality in their beauty products. HABA Laboratories focuses on providing high-quality skincare solutions and has established a strong presence in the Japanese market, with a growing international footprint.
How the Company Makes MoneyHABA Laboratories, Inc. generates revenue primarily through the sale of its skincare and cosmetic products. The company's key revenue streams include direct sales through its retail stores and online platforms, as well as distribution through third-party retailers and partners. HABA Laboratories leverages its brand reputation for safety and quality to attract and retain a loyal customer base. The company also engages in marketing and promotional activities to expand its market reach and increase sales. Strategic partnerships with retailers and distributors help HABA Laboratories to extend its product availability and enhance its earnings potential.

HABA Laboratories, Inc. Financial Statement Overview

Summary
HABA Laboratories shows a mixed financial picture. Revenue declines and inconsistent profitability challenge the income statement, while the balance sheet remains strong with low leverage and solid equity. Improving cash flow generation is a positive sign, though historical volatility presents challenges. The company demonstrates resilience in financial stability but needs to address profitability and growth concerns.
Income Statement
55
Neutral
HABA Laboratories has faced challenges with revenue growth, showing an overall declining trend from the 2020 peak. The gross profit margin remains robust, suggesting efficient cost management, but net income has fluctuated significantly, impacting net profit margins negatively in recent years. The EBIT and EBITDA margins have been erratic, reflecting operational challenges and inconsistent profitability.
Balance Sheet
70
Positive
The balance sheet shows strong equity with a favorable equity ratio, indicating financial stability. The debt-to-equity ratio is low, reducing leverage risks. However, the return on equity is unstable due to fluctuating net income. Overall, the company maintains a solid asset base with a strong equity cushion.
Cash Flow
60
Neutral
Cash flow analysis reveals improving operating cash flow in the most recent period, which is a positive sign. Yet, the company has struggled with free cash flow growth, and previous periods showed volatility. The operating cash flow to net income ratio indicates better cash generation relative to profits recently, but historical instability remains a concern.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue12.06B12.32B12.04B12.91B14.31B
Gross Profit7.99B8.03B8.17B8.79B10.20B
EBITDA811.56M-1.31B17.05M448.30M960.14M
Net Income576.57M-2.12B-707.87M-269.03M216.42M
Balance Sheet
Total Assets12.34B12.43B14.66B15.69B17.44B
Cash, Cash Equivalents and Short-Term Investments4.74B3.96B4.82B5.65B5.66B
Total Debt1.82B2.36B2.03B2.56B3.92B
Total Liabilities3.42B3.92B3.88B4.05B5.40B
Stockholders Equity8.93B8.51B10.77B11.64B12.04B
Cash Flow
Free Cash Flow1.48B-1.02B-232.69M1.53B-346.95M
Operating Cash Flow1.62B-587.92M55.96M1.71B534.71M
Investing Cash Flow-147.18M-441.79M-214.40M-216.49M-925.08M
Financing Cash Flow-689.49M171.06M-676.32M-1.51B825.38M

HABA Laboratories, Inc. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1650.00
Price Trends
50DMA
1686.58
Negative
100DMA
1714.67
Negative
200DMA
1717.36
Negative
Market Momentum
MACD
-10.75
Negative
RSI
44.63
Neutral
STOCH
61.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Neutral. The current price of 1650 is above the 20-day moving average (MA) of 1644.80, below the 50-day MA of 1686.58, and below the 200-day MA of 1717.36, indicating a neutral trend. The MACD of -10.75 indicates Negative momentum. The RSI at 44.63 is Neutral, neither overbought nor oversold. The STOCH value of 61.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4925.

HABA Laboratories, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
¥11.88B57.95
3.07%4.75%-83.63%
68
Neutral
¥11.10B15.59
5.92%12.45%-3.65%
65
Neutral
$27.19B15.58-4.44%2.56%1.05%4.97%
61
Neutral
¥6.23B10.81
2.43%-2.13%
57
Neutral
¥6.11B158.30
1.58%-9.81%
57
Neutral
¥8.02B10.99
-17.95%
45
Neutral
¥4.93B36.16
1.74%0.10%-239.09%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4925
HABA Laboratories, Inc.
1,648.00
-318.66
-16.20%
JP:4926
C'BON COSMETICS Co., Ltd.
1,151.00
-225.64
-16.39%
JP:4929
ADJUVANT HOLDINGS CO., LTD.
755.00
-102.44
-11.95%
JP:4932
Almado, Inc.
1,098.00
-75.32
-6.42%
JP:4934
Premier Anti-Aging Co., Ltd.
919.00
25.00
2.80%
JP:4936
AXXZIA, Inc.
489.00
-414.75
-45.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 17, 2025